Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 4/20 | 0.39 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20778035 | 1.00 | RNASEL (0.39) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL30292623 | 1.00 | RNASEL (0.39) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL23621433 | 1.00 | RNASEL (0.39) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL26435596 | 1.00 | RNASEL (0.39) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL22375444 | 0.97 | RNASEL (0.40) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL20778026 | 0.91 | RNASEL (0.45) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL26442453 | 0.91 | RNASEL (0.45) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL30292621 | 0.91 | RNASEL (0.45) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL26294855 | 0.91 | RNASEL (0.38) | RNASELP2RY2P2RY4P2RY12P2RY14 | |
| SCHEMBL26294872 | 0.91 | RNASEL (0.38) | RNASELP2RY2P2RY4P2RY12P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205347-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| WO-2019161171-A1 | NANOPARTICLE FORMULATIONS OF STING AGONISTS | SPEROVIE BIOSCIENCES, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205347-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, MAVS, IRF3 | RNASEL 1374/4885P2RY2 1016/4885P2RY4 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.